Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Speeding up Science: How We Can Stop the Decline of Drug Production as Scientific Information Increases

Posted on October 28th, 2015 by

Chemistry

redundant-info

Every 9 years, scientific output is doubling and more information is being made available to the world’s top scientists. Contrary to common sense and public opinion, for every 1 billion invested in drug development, the number of drugs approved has been halved every 9 years, and approximately 70% of drugs sold in the US today are generics. Continue reading “Speeding up Science: How We Can Stop the Decline of Drug Production as Scientific Information Increases” »

Using Intelligent and Connected Taxonomies to Power Insightful Reasearch

Posted on October 27th, 2015 by

Chemistry

Elsevier-Whitepaper-The-Means-to-Use-Information-

Information is useful only when it can be found. Taxonomies offer obvious organizational benefits, but their impact on database usability is far-reaching.
Read an excerpt from the Elsevier whitepaper, The Means to Use Information, to discover how to maximize taxonomies and learn how to utilize intelligent and connected taxonomies to take your insightful research to the next level. Continue reading “Using Intelligent and Connected Taxonomies to Power Insightful Reasearch” »

Pharmacovigilance: Rethinking Literature Monitoring and Review

Posted on October 27th, 2015 by

Pharmacovigilance

pills

Pharmacovigilance is defined as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems.” Under that umbrella, government agencies in the United States, the European Union and other parts of the world have developed diverse and increasingly complex regulatory requirements. Continue reading “Pharmacovigilance: Rethinking Literature Monitoring and Review” »

EMA’s Medical Literature Monitoring: Shakedown or Shakeup

Posted on October 27th, 2015 by

Pharmacovigilance

Medical Literature

Although, quite a lot of existing flows have to change and new ones have to be implemented, there are, also, quite a lot of benefits, most of them for EMA, and some, not so obvious, for the MAH’s. Of these last ones, many are found by looking at the information, now made available by EMA, as an information professional in a pharmacovigilance context, as well as a pharmacovigilance analyst in an information rich environment.

Read more about EMA’s Medical Literature Monitoring

 

Data, Data and More Data

Posted on October 23rd, 2015 by

Chemistry

QUOSA_000015928077_Large

Read an excerpt from the Elsevier whitepaper, Big Data, Wider Mindset to discover how systems biology and systems chemistry enable a holistic view of a biological system that is more than it’s sum of molecular components.

Continue reading “Data, Data and More Data” »

  1. 1
  2. …
  3. 36
  4. 37
  5. 38


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.